University of Medicine and Pharmacy "Carol Davila", Euroecolab, Bucharest, Romania.
Emergency Institute for Cardiovascular Diseases "Prof. Dr. C. C. Iliescu", Şos. Fundeni 258, Sector 2, 022328, Bucharest, Romania.
J Echocardiogr. 2020 Sep;18(3):137-148. doi: 10.1007/s12574-020-00467-9. Epub 2020 Apr 16.
Hypertrophic cardiomyopathy (HCM) is the most frequent cardiac disease with genetic substrate, affecting about 0.2-0.5% of the population. While most of the patients with HCM have a relatively good prognosis, some are at increased risk of adverse events. Identifying such patients at risk is important for optimal treatment and follow-up. While clinical and electrocardiographic information plays an important role, echocardiography remains the cornerstone in assessing patients with HCM. In this review, we discuss the role of echocardiography in diagnosing HCM, the key features that differentiate HCM from other diseases and the use of echocardiography for risk stratification in this setting (risk of sudden cardiac death, heart failure, atrial fibrillation and stroke). The use of modern echocardiographic techniques (deformation imaging, 3D echocardiography) refines the diagnosis and prognostic assessment of patients with HCM. The echocardiographic data need to be integrated with clinical data and other information, including cardiac magnetic resonance, especially in challenging cases or when there is incomplete information, for the optimal management of these patients.
肥厚型心肌病(HCM)是最常见的具有遗传基础的心脏病,影响约 0.2-0.5%的人群。虽然大多数 HCM 患者的预后相对较好,但有些患者发生不良事件的风险增加。识别此类高危患者对于最佳治疗和随访非常重要。虽然临床和心电图信息起着重要作用,但超声心动图仍然是评估 HCM 患者的基石。在这篇综述中,我们讨论了超声心动图在诊断 HCM 中的作用、区分 HCM 与其他疾病的关键特征以及在这种情况下进行风险分层(心源性猝死、心力衰竭、心房颤动和中风的风险)的应用。现代超声心动图技术(应变成像、3D 超声心动图)可细化 HCM 患者的诊断和预后评估。超声心动图数据需要与临床数据和其他信息(包括心脏磁共振)相结合,尤其是在具有挑战性的病例或信息不完整的情况下,以便为这些患者提供最佳管理。